

Masatsugu Tanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1827598/publications.pdf>

Version: 2024-02-01

108
papers

998
citations

567144

15
h-index

552653

26
g-index

108
all docs

108
docs citations

108
times ranked

1215
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 330-338.	2.0	100
2	Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 302-307.	2.0	49
3	Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. <i>Blood Advances</i> , 2019, 3, 3626-3634.	2.5	39
4	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. <i>American Journal of Hematology</i> , 2020, 95, 343-353.	2.0	39
5	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1553-1559.	2.0	35
6	Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies. <i>International Journal of Hematology</i> , 2011, 93, 368-374.	0.7	34
7	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 519-528.	2.0	34
8	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 3255-3266.	1.7	32
9	Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2017-2022.	2.0	30
10	The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. <i>Leukemia Research</i> , 2012, 36, 699-703.	0.4	29
11	Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of <i>CDX2</i> and <i>IDH1/2</i> mutations. <i>Blood</i> , 2022, 139, 1850-1862.	0.6	28
12	Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 722-728.	1.3	25
13	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	0.6	23
14	Detection of Mycobacterium tuberculosis-derived DNA in circulating cell-free DNA from a patient with disseminated infection using digital PCR. <i>International Journal of Infectious Diseases</i> , 2018, 66, 80-82.	1.5	22
15	Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 624-636.	2.5	19
16	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2105-2114.	2.0	17
17	Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 1051-1061.	2.5	17
18	Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, e620-e628.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1132-1138.	3.3	16
20	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	16
21	Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 517-525.	2.0	15
22	Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 415-421.	0.2	15
23	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	3.2	14
24	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1317-1325.	1.3	14
25	Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 463-471.	2.0	13
26	Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>British Journal of Haematology</i> , 2020, 190, 84-92.	1.2	13
27	Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2017, 105, 623-630.	0.7	12
28	Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. <i>Leukemia</i> , 2019, 33, 2610-2618.	3.3	12
29	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
30	Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. <i>International Journal of Hematology</i> , 2019, 109, 673-683.	0.7	11
31	Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1730-1743.	2.0	10
32	Identification of Lymphocyte Subsets Associated with Outcomes in Patients with Hematological Malignancy Following Allogeneic Stem Cell Transplantation: A Single Institute Study. <i>Blood</i> , 2018, 132, 2115-2115.	0.6	10
33	Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2016, 103, 444-452.	0.7	9
34	Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1332-1337.	0.6	9
35	Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia. <i>International Journal of Hematology</i> , 2019, 109, 162-168.	0.7	9
36	A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 162-170.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1363-1370.	2.0	8
38	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	1.3	8
39	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. <i>International Journal of Hematology</i> , 2019, 109, 711-717.	0.7	7
40	Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 171-177.	2.0	7
41	Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. <i>American Journal of Hematology</i> , 2020, 95, 251-257.	2.0	7
42	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. <i>Blood Advances</i> , 2021, 5, 584-592.	2.5	7
43	Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1352-1363.	1.3	7
44	Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. <i>Bone Marrow Transplantation</i> , 2021, 56, 2302-2304.	1.3	7
45	Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 1403-1411.	0.6	6
46	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <i>Blood Advances</i> , 2019, 3, 1750-1760.	2.5	6
47	Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. <i>Annals of Hematology</i> , 2021, 100, 1849-1861.	0.8	6
48	Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 314.e1-314.e10.	0.6	6
49	Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2231-2240.	1.3	6
50	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 574-584.	2.5	6
51	Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 398.e1-398.e9.	0.6	6
52	Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. <i>Bone Marrow Transplantation</i> , 2020, 55, 249-252.	1.3	5
53	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2393-2404.	0.8	5
54	Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up. <i>Journal of Cancer Survivorship</i> , 2022, 16, 1004-1015.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II–IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group. <i>Annals of Hematology</i> , 2021, 100, 3029-3038.	0.8	5
56	Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 209.e1-209.e9.	0.6	5
57	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. <i>Bone Marrow Transplantation</i> , 2020, 55, 1337-1346.	1.3	4
58	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 998-1004.	2.0	4
59	A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2021, , 1.	0.7	4
60	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. <i>BMJ Open</i> , 2020, 10, e040467.	0.8	4
61	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplant Outcomes?: A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy (KSGCT). <i>Blood</i> , 2012, 120, 1993-1993.	0.6	4
62	Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation. <i>International Journal of Hematology</i> , 2022, 116, 594-602.	0.7	4
63	Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia. <i>International Journal of Hematology</i> , 2015, 102, 451-459.	0.7	3
64	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy–refractory or relapsed disease prior to allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 403-413.	1.2	3
65	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 2098-2108.	1.3	3
66	Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 376-389.	0.6	3
67	Personalized prediction of overall survival in patients with AML in non–complete remission undergoing allo–HCT. <i>Cancer Medicine</i> , 2021, 10, 4250-4268.	1.3	2
68	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2842-2848.	1.3	2
69	Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients. <i>Scientific Reports</i> , 2021, 11, 18046.	1.6	2
70	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. <i>Blood Cancer Journal</i> , 2021, 11, 159.	2.8	2
71	Impact of HLA disparity on the risk of overall mortality in patients with grade II–IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2990-2996.	1.3	2
72	Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 800.e1-800.e8.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Altered effect of killer immunoglobulin-like receptorâ€“ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 3059-3067.	1.3	2
74	Elevated Serum Ferritin Predicts the Delay of Engraftment and High Incidence of Blood Stream Infection within 100 Days After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 1135-1135.	0.6	2
75	Prognostic Impact of Delayed Platelet Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancy. <i>Blood</i> , 2016, 128, 3407-3407.	0.6	2
76	HLA 1â€“3 antigenâ€“mismatched related peripheral blood stem cells transplantation using lowâ€“dose antithymocyte globulin versus unrelated cord blood transplantation. <i>American Journal of Hematology</i> , 2022, 97, 311-321.	2.0	2
77	Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 153.e1-153.e11.	0.6	2
78	Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. <i>Bone Marrow Transplantation</i> , 2022, 57, 1171-1179.	1.3	2
79	Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT. <i>Annals of Hematology</i> , 2020, 99, 2927-2937.	0.8	1
80	Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. <i>Annals of Hematology</i> , 2021, 100, 2763-2771.	0.8	1
81	Remission Induction Treatment for 6 Patients of Jehovahâ€™s Witnesses with De Novo Acute Leukemia.. <i>Blood</i> , 2006, 108, 4553-4553.	0.6	1
82	A case of multiple brain abscesses due to <i>Bacillus cereus</i> during induction therapy for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 114, 637-638.	0.7	1
83	Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis. <i>Internal Medicine</i> , 2020, 59, 1947-1956.	0.3	1
84	HLA-B Leader Dimorphism Impacts on Outcomes of HLA-Matched Related/Unrelated Transplantation: Analysis of the Japanese Society for Transplantation and Cellular Therapy. <i>Blood</i> , 2021, 138, 2919-2919.	0.6	1
85	Ideal Body Weight Is Useful For Predicting Neutrophil Engraftment and Platelet Recovery for Overweight and Obese Recipients in Single-Unit Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 504.e1-504.e7.	0.6	1
86	Successful hemochromatosis following allogeneic stem cell transplantation for acute lymphoblastic leukemia. <i>Journal of Hematopoietic Cell Transplantation</i> , 2012, 1, 33-36.	0.1	0
87	Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 232-242.	1.3	0
88	Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 646-654.	1.3	0
89	Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 70.e1-70.e8.	0.6	0
90	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-7.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Prevalence of organ symptoms in allo-HCT survivors and their impact on work and daily life. <i>Journal of Illness, 2021, 10, 172-182.</i>	0.0	0
92	Prognostic Impact of Posttransplantation Serum Ferritin In Allogeneic Stem Cell Transplantation for Leukemia or Myelodysplastic Syndrome.. <i>Blood, 2010, 116, 3444-3444.</i>	0.6	0
93	Risk Factors for Developing Human Herpes Virus-6 Encephalitis and Clinical Significance of Antiviral Therapy In Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood, 2010, 116, 4538-4538.</i>	0.6	0
94	Retrospective Study of the Utility of Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 In Patients with Follicular Lymphoma Uniformly Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, and Prednisone. <i>Blood, 2010, 116, 3100-3100.</i>	0.6	0
95	Multicenter Validation of the Scoring System of Pre-Transplant Serum Ferritin and Disease Risk in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood, 2011, 118, 2032-2032.</i>	0.6	0
96	Clinical Significance of Addition of Cytarabine or Thiotepa to TBI/CY Regimen.. <i>Blood, 2012, 120, 3028-3028.</i>	0.6	0
97	Body Mass Index Is a Prognostic Factor in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Multi-Institutional Study in Japan. <i>Blood, 2015, 126, 1316-1316.</i>	0.6	0
98	Prognostic Impact of Pre-Transplant Serum C-Reactive Protein in Patients Receiving a Single-Unit Unrelated Cord Blood Transplantation. <i>Blood, 2016, 128, 5853-5853.</i>	0.6	0
99	Impact of the Difference in Body Mass Index at Transplantation from That at Diagnosis for Graft-Versus-Host Disease-Free, Relapse-Free Survival in Acute Myeloid Leukemia. <i>Blood, 2016, 128, 3482-3482.</i>	0.6	0
100	Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia with Pre-Transplant Conditioning Using Fludarabine, Reduced-Dose Cyclophosphamide, and Low-Dose Thymoglobulin:Ã, Ksgct Prospective Study. <i>Blood, 2018, 132, 2101-2101.</i>	0.6	0
101	Impact of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect Based on Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood, 2019, 134, 4522-4522.</i>	0.6	0
102	Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan. <i>Blood, 2019, 134, 2045-2045.</i>	0.6	0
103	Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia. <i>Blood, 2021, 138, 1790-1790.</i>	0.6	0
104	Cytomegalovirus Gastroenteritis in Patients with Acute Graft-Versus-Host Disease. <i>Blood, 2021, 138, 3918-3918.</i>	0.6	0
105	Significance of Marker Chromosome on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for AML. <i>Blood, 2020, 136, 40-41.</i>	0.6	0
106	Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT). <i>Blood, 2020, 136, 28-29.</i>	0.6	0
107	Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. <i>Bone Marrow Transplantation, 2022, , .</i>	1.3	0
108	Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. <i>Hematology, 2022, 27, 620-628.</i>	0.7	0